Trader consensus on Polymarket reflects a 91.5% implied probability against a new pandemic in 2026, driven by the absence of any novel pathogen achieving sustained human-to-human transmission across multiple countries, per WHO and CDC surveillance data through late April. Ongoing threats like clade Ib mpox (over 181,000 global cases since 2022, mostly contained with vaccines) and sporadic H5N1 avian influenza human infections (under 900 since 1997, no efficient spread) remain below pandemic thresholds, bolstered by enhanced global preparedness post-COVID, including R&D roadmaps for priority pathogens. Respiratory viruses, including COVID-19's BA.3.2 "Cicada" variant detected in March, show seasonal patterns without exponential surges. Realistic challenges include unexpected zoonotic spillovers or viral mutations enabling airborne transmission, with key upcoming WHO epi updates and flu season monitoring in Q3-Q4 potentially shifting sentiment.